the kENUP foundation


Barbados’ Prime Minister Mia Amor Mottley announces transatlantic bridge between the Caribbean, Latin America and Africa to develop and manufacture pharmaceuticals for global public health



Today, on the sidelines of COP27, Prime Minister of Barbados Mia Amor Mottley, President of the Co-operative Republic of Guyana H.E. Mohamed Irfaan Ali, and President of the Republic of Rwanda,. H.E. Paul Kagame met in Sharm El-Sheikh to discuss the furthering of pharmaceutical equity for global public health.


In attendence were, among others, President of the European Commission Ursula von der Leyen, Director-General of the World Health Organization (WHO) Dr Tedros Adhanom Ghebreyesus, Acting Director Dr. Ahmed Ogwell Ouma of Africa CDC, President Dr Werner Hoyer of the European Investment Bank (EIB), Prof Senait Fisseha, MD., JD, as well as kENUP Foundation Chairman Holm Keller.

 

The key recommendation emanating from the meeting is an inter-governmental South-South cooperation initiative aiming at the development and manufacturing of essential, contemporary pharmaceuticals for the populations of Latin America, the Caribbean, and Africa within their respective continents by 2040. Initially, it is intended for the cooperation to focus on next generation oncological drugs, preventive and therapeutic vaccines, as well as on modalities for women’s health. It is also stipulated that all manufacturing sites related to this endeavor will be in full compliance with the relevant stipulations of the COP21 Paris Agreement. 


The leaders of the countries and organizations which have launched this initiative have emphasized that all interested countries in the Caribbean, Latin America and African region are invited to join.

The Communiqué and the official press release can be downloaded here.


kENUP Foundation is a non-profit public benefit foundation supporting research-based innovation in the wider health industries for societal benefit.

kENUP initiates and facilitates public and private investment into innovations with the potential to improve the livelihood of every citizen. The development of such innovations is often hampered by failing markets. With our intervention, we aim to change that.  

kENUP supports the development of scientific innovations into sustainable business propositions and makes them financeable by public and private institutions, and civil society partners. Such financing is typically aimed at de-risking product development processes that otherwise cannot be pursued. .
kENUP focuses on vaccines, human monoclonal antibodies, nanobodies, therapeutics, cell therapies, diagnostics, and the production of biologicals. The platform technologies necessary for their deployment are in the center of our work. Through them, we aim to make effective and affordable products globally available, including to the Global South. 

kENUP believes in the power of science diplomacy and is actively supporting the peace process in the Middle East.

kENUP initiates novel financing instruments aimed at fighting a particular disease or supporting a specific industry, like the EU Malaria Fund, the co-investment scheme of the European Union with the State of Israel dedicated to bio-convergence, or the EU umbrella funding instrument API for Africa. 

kENUP covers its costs through moderate nominal accomplishment fees only after the successful conclusion of a project. As a non-profit public benefit foundation, we can only support initiatives our Board of Directors unanimously considers as eligible. kENUP Foundation does not accept donations from individuals or corporations. We publish our activities in the European Union’s Transparency Register. .
kENUP Foundation is a non-profit public benefit foundation supporting research-based innovation in the wider health industries for societal benefit.
kENUP initiates and facilitates public and private investment into innovations with the potential to improve the livelihood of every citizen. The development of such innovations is often hampered by failing markets. With our intervention, we aim to change that. 
kENUP supports the development of scientific innovations into sustainable business propositions and makes them financeable by public and private institutions, and civil society partners. Such financing is typically aimed at de-risking product development processes that otherwise cannot be pursued. 
kENUP focuses on vaccines, human monoclonal antibodies, nanobodies, therapeutics, cell therapies, diagnostics, and the production of biologicals. The platform technologies necessary for their deployment are in the center of our work. Through them, we aim to make effective and affordable products globally available, including to the Global South. 
kENUP believes in the power of science diplomacy and is actively supporting the peace process in the Middle East. 
kENUP initiates novel financing instruments aimed at fighting a particular disease or supporting a specific industry, like the EU Malaria Fund, the co-investment scheme of the European Union with the State of Israel dedicated to bio-convergence, or the EU umbrella funding instrument API for Africa. 
kENUP covers its costs through moderate nominal accomplishment fees only after the successful conclusion of a project. As a non-profit public benefit foundation, we can only support initiatives our Board of Directors unanimously considers as eligible. kENUP Foundation does not accept donations from individuals or corporations. We publish our activities in the European Union’s Transparency Register. .